Canopy Growth stock analysis
Canopy Growth (CGC) Stock Price & Analysis
CGC Stock Chart & Stats
- Day’s Range
- $0.59 - $0.62
- 52-Week Range
- $0.58 - $2.38
- Previous Close
- $0.59
- Volume
- N/A
- Average Volume (3M)
- 2.68M
- Market Cap
- $265.03M
- Enterprise Value
- $494.26M
- Total Cash (Recent Filing)
- $336.63M
- Total Debt (Recent Filing)
- $277.33M
- Price to Earnings (P/E)
- ―
- Beta
- 1.53
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
International Expansion
Rapid international revenue growth, expanded European access, and entry into the U.K. broaden Canopy’s regulated-market footprint. Greater geographic reach can diversify revenue, strengthen distribution capabilities, and create a larger platform for future medical cannabis product expansion.
EU GMP Platform
End-to-end EU GMP certification covering cultivation through manufacturing and packaging is a meaningful operating capability. It supports patient-ready product expansion, improves access to European markets, and creates infrastructure for scaling regulated international sales.
Operating Efficiency
Planned MTL synergies and streamlined manufacturing and distribution could reduce the cost base as integration progresses. Lower SG&A and better operating leverage would support margin recovery and improve the company’s ability to convert revenue growth into adjusted EBITDA.
Bears Say
Persistent Unprofitability
Severe negative margins show that revenue growth has not yet translated into sustainable earnings. Continued losses can erode equity, limit internal funding for expansion, and leave the business dependent on operational improvements before profitability becomes durable.
Negative Cash Generation
Ongoing operating and free-cash-flow deficits indicate that the business is still consuming cash despite improving revenue trends. Until profitability changes this pattern, Canopy may need financing or balance-sheet resources to support operations and strategic investment.
Margin And Cost Pressure
Lower gross margin directly reduces the contribution available to cover operating expenses and fund growth. The reimbursement-rate reduction also highlights exposure to regulated-channel economics, while weaker unit margins make the path to sustainable EBITDA more demanding.
Canopy Growth News
CGC FAQ
What was Canopy Growth’s price range in the past 12 months?
What is Canopy Growth’s market cap?
When is Canopy Growth’s upcoming earnings report date?
How were Canopy Growth’s earnings last quarter?
Is Canopy Growth overvalued?
Does Canopy Growth pay dividends?
What is Canopy Growth’s EPS estimate?
How many shares outstanding does Canopy Growth have?
What happened to Canopy Growth’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Canopy Growth?
What is the TipRanks Smart Score and how is it calculated?
Canopy Growth Stock Smart Score
Company Description
Canopy Growth
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods. Its extensive product line features dried cannabis flower, a variety of extracts and concentrates, beverages, edible gummies, and vaporization products. Canopy Growth commercializes these goods under numerous well-known brands such as Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra. Formed in 2009, the enterprise initially operated as Tweed Marijuana Inc. before adopting its current name, Canopy Growth Corporation, in September 2015. Its principal office is located in Smiths Falls, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Luc Mongeau
- Employees
- 1,128
- Website
- www.canopygrowth.com
- Address
- 1 Hershey Drive, Smiths Falls, ON, K7A 0A8, CA
Canopy Growth (CGC) Earnings & Revenues
CGC Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Canopy reported strong consolidated, cannabis, international, medical, and adult-use revenue growth; improved operating efficiency; a narrower adjusted EBITDA loss; substantial liquidity; and progress in cultivation, EU GMP certification, and international expansion. The main negative factors were the 44% decline in Storz & Bickel revenue, lower consolidated gross margin due primarily to the Veteran Affairs Canada reimbursement-rate reduction, ongoing negative adjusted EBITDA, and the company's acknowledgment that cultivation costs are not yet best in class. Management nevertheless expressed confidence in achieving positive adjusted EBITDA in the second half of fiscal 2027 and in realizing further benefits from cultivation and operating initiatives.
View all CGC earnings summariesCGC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |













